Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A

NCT06155955 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Severe Hemophilia A Without Inhibitor
Joint Bleed

Interventions

DRUG: "Emicizumab", "HEMLIBRA®"

Sponsor

Chulalongkorn University